logo

For the Inventor, By the Inventor

Rockville, MD, United States of America

Glycomimetics, Inc.


USPTO Granted Patents = 41

% Expired Patents = 14.6


Forward Citations = 450

Loading Chart...
Loading Chart...

24 inventors (with patents filed for the assignee):

goldMedal John L Magnani (39 out of 48 patents)

silverMedal Arun K Sarkar (21 out of 22 patents)

bronzeMedal John Tinsman Patton, Jr (11 out of 12 patents)

4.  Myung-Gi Baek (10 out of 10 patents)

5.  John M Peterson (8 out of 11 patents)

6.  Yanhong Li (6 out of 6 patents)

7.  Beat Ernst (6 out of 13 patents)

8.  Frank Elbert Anderson, Iii (6 out of 10 patents)

9.  Sergei A Svarovsky (4 out of 7 patents)

10.  Leonard M Williams (3 out of 3 patents)

11.  Yusufbhai U Vohra (3 out of 3 patents)

12.  Yusuf U Vohra (2 out of 2 patents)

13.  William E Fogler (2 out of 7 patents)

14.  Indranath Ghosh (2 out of 4 patents)

15.  Jason Nogueira (2 out of 2 patents)


Core Competencies:
E-Selectin Antagonists
Galectin-3 Inhibitors
Multimeric Compounds
Heterobifunctional Inhibitors
Cancer Treatment
Cardiovascular Disease
Mobilization Methods
Glycomimetic Compounds
Sickle Cell Disease
Pan-Selectin Inhibitors
Chemokine Receptors
Selectin-Mediated Function

41 patents:

1. 11987598 - E-selectin antagonist compounds, compositions, and methods of use (2024-05-21),
2. 11878026 - Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists (2024-01-23),
3. 11873317 - Galectin-3 inhibiting c-glycosides (2024-01-16),
4. 11845771 - Heterobifunctional inhibitors of E-selectin and galectin-3 (2023-12-19),
5. 11780873 - Highly potent multimeric e-selectin antagonists (2023-10-10),
6. 11712446 - Methods of mobilizing marrow infiltrating lymphocytes and uses thereof (2023-08-01),
7. 11707474 - Methods for treating acute myeloid leukemia and related conditions (2023-07-25),
8. 11548908 - Heterobifunctional inhibitors of E-selectin and galectin-3 (2023-01-10),
9. 11433086 - Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 (2022-09-06),
10. 11332491 - E-selectin antagonist compounds, compositions, and methods of use (2022-05-17),
11. 11291678 - Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin (2022-04-05),
12. 11197877 - Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists (2021-12-14),
13. 11072625 - Highly potent multimeric e-selectin antagonists (2021-07-27),
14. 11045485 - Glycomimetic inhibitors of PA-IL and PA-IIL lectins (2021-06-29),
15. 10766916 - E-selectin antagonist compounds, compositions, and methods of use (2020-09-08),
Glycomimetics, Inc. is a biotechnology company based in Rockville, Maryland, focused on the discovery and development of innovative therapies for serious diseases. The company specializes in glycomimetic compounds that target critical pathways in cancer and cardiovascular diseases. Its core technologies include E-selectin antagonists, galectin-3 inhibitors, and heterobifunctional inhibitors, which are designed to address unmet medical needs, particularly in acute myeloid leukemia and T-cell checkpoint inhibition.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Glycomimetics, Inc.
41 Patents

#16 in Rockville, MD

#98 in Maryland

#8,433 in US

#16,686 in the World

Rockville, MD (US)
Rockville, MD, United States of America

Glycomimetics, Inc.

Forward Citations = 450

24 inventors:

goldMedal John L Magnani (39 out of 48 patents)

silverMedal Arun K Sarkar (21 out of 22 patents)

bronzeMedal John Tinsman Patton, Jr (11 out of 12 patents)

4.  Myung-Gi Baek (10 out of 10 patents)

5.  John M Peterson (8 out of 11 patents)

Please report any incorrect information to [email protected]
Loading…